Skip to content

A randomized controlled trial for the Shenhuang granule in the prevention and treatment of sepsis based on truncation and torsion strategy

A randomized, double-Blind, controlled, multicenter clinical trial for Shenhuang granule in the treatment of sepsis based on truncation and torsion strategy

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2024000251
Enrollment
Unknown
Registered
2024-08-16
Start date
2024-05-20
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Interventions

Sponsors

LongHua Hospital Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1.Age at onset between 18 and 90 years; 2.Meets the diagnostic criteria for sepsis (Sepsis-3): (i) infection, (ii) life-threatening organ dysfunction with a SOFA score = 2 points; 3.Voluntarily participates in the trial and signs the informed consent form.

Exclusion criteria

Exclusion criteria: 1.Diagnosis of sepsis for more than 48 hours; 2.Pregnant or lactating women; 3.Severe primary diseases affecting survival, including: uncontrolled malignant tumors with multiple metastases that cannot be resected, hematological diseases, and HIV, etc.; 4.Hepatic or renal dysfunction with a single SOFA score of = 3 points for liver or kidney; 5.Continuous use of immunosuppressants or organ transplant recipients within the past 6 months; 6.Use of steroids within 7 days before enrollment, equivalent to a methylprednisolone dose of = 20 mg/day; 7.Participation in other clinical trials within the past 30 days; 8.Expected to die within 48 hours, patients refusing active treatment (SOFA = 15 or APACHE II = 30); 9.Known allergy to components of the study drug or hypersensitivity.

Design outcomes

Primary

MeasureTime frame
28-day all-cause mortality;60-day all-cause mortality;

Secondary

MeasureTime frame
Changes in liver and kidney function indicators;Changes in GCS score, RASS score, and CAM-ICU score;Changes in APACHE II score;Changes in microcirculation and arterial blood gas indicators;Changes in pulmonary surfactant protein A levels;Duration of ICU stay;Changes in neurological examination indicators;Changes in coagulation indicators;Length of hospital stay;Changes in immune, inflammatory, and metabolic indicators;Changes in traditional Chinese medicine syndromes and scores;Changes in cardiac indicators;Changes in SOFA score;

Countries

China

Contacts

Public ContactBangjiang Fang

LongHua Hospital Shanghai University of Traditional Chinese Medicine

fangbji@163.com+86 189 1776 3257

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026